Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals Stock
The price for the Acadia Pharmaceuticals stock decreased slightly today. Compared to yesterday there is a change of -€0.230 (-1.000%).
With 28 Buy predictions and 1 Sell predictions Acadia Pharmaceuticals is one of the favorites of our community.
As a result the target price of 29 € shows a positive potential of 29.18% compared to the current price of 22.45 € for Acadia Pharmaceuticals.
For the coming years our community has positive and negative things to say abot the Acadia Pharmaceuticals stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Acadia Pharmaceuticals in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acadia Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals | -1.000% | 2.840% | 1.354% | 7.519% | -3.358% | -16.231% | 23.081% |
| Ligand Pharmaceuticals | -1.540% | -3.759% | -7.246% | 118.803% | 54.217% | 316.260% | 167.056% |
| United Therapeutics | -1.560% | -3.421% | -5.275% | 86.343% | 5.055% | 103.398% | 189.613% |
| Ionis Pharmaceuticals Inc. | -2.030% | -9.692% | -36.406% | 19.220% | -33.917% | 19.125% | 43.391% |
Comments
ACADIA Pharmaceuticals (ACAD) had its price target raised by BMO Capital Markets from $34.00 to $36.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (ACAD) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (ACAD) had its price target raised by Bank of America Corporation from $29.00 to $30.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat